ADDED
2015 Equity Incentive Plan 2015 Share Repurchase Program Board of Directors-approved share repurchase program 2025 Plan ImmunityBio, Inc.
2025 Equity Incentive Plan 3M IPC 3M Innovative Properties Company 3PL Agent logistics agent 401(k) Plan 401(k) retirement and savings plan AAHI Access to Advanced Health Institute ACA Affordable Care Act ADCC antibody-dependent cellular cytotoxicity AI artificial intelligence AKS Anti-Kickback Statute ALC absolute lymphocyte count Altor Altor BioScience, LLC America Invents Act Leahy-Smith America Invents Act Amyris Amyris, Inc.
Department of Commerce, Bureau of Industry and Security BLA Biologics License Application BPCIA Biologics Price Competition and Innovation Act of 2009 Brink Brink Biologics, Inc.
Cambridge Cambridge Equities, LP Cancer BioShield platform our first-in-class immunotherapy strategy designed to restore immune competence by reversing lymphopenia the loss of functional immune cells caused by cancer itself and by conventional treatments such as chemotherapy, radiation and immunotherapy.
CAP community-acquired pneumonia CAR chimeric antigen receptor CCPA California Consumer Privacy Act of 2018 CEO chief executive officer CFO chief financial officer cGMP current Good Manufacturing Practice China when used in connection with the RIPA, People s Republic of China, Hong Kong and any territories controlled by the People s Republic of China CHMP Committee for Medicinal Products for Human Use CI confidence interval CIO chief information officer CIS carcinoma in situ Clinic Immuno-Oncology Clinic, Inc.
NantMobile NantMobile, LLC NantWorks NantWorks, LLC, a related party NCCN National Comprehensive Cancer Network NC 2015 Plan NantCell, Inc.
Securities and Exchange Commission Section 404 Section 404 of the Sarbanes-Oxley Act of 2002 Securities Act Securities Act of 1933, as amended Serum Institute Serum Institute of India Private Limited SFDA Saudi Food and Drug Authority Sorrento Sorrento Therapeutics, Inc.
v Term Definition SPOA Stock Purchase and Option Agreement SRLY separate return limitation year TAA tumor-associated antigen TCJA Tax Cuts and Jobs Act of 2017 Term SOFR Term Secured Overnight Financing Rate Test Date when used in connection with the RIPA, December 31, 2029 TGF- transforming growth factor beta t-haNK targeted high-affinity NK (CAR-NK) TLR toll-like receptor TNBC triple-negative breast cancer Tregs regulatory T cells TriAd Triple Antigen (CEA, MUC1, Brachyury) TTFields tumor treating fields UK United Kingdom UK GDPR UK Data Protection Act of 2018 U.S.
Forward-looking statements include, but are not limited to: our ability to successfully commercialize ANKTIVA globally in NMIBC, NSCLC or other indications or any future approved products in the U.S.
and global economies, and materially and adversely affect our business and/or our future BLA submissions; the impact on us, if any, if the CVRs held by former Altor stockholders become due and payable; and regulatory developments in the U.S.
REMOVED
2015 Equity Incentive Plan 2015 Share Repurchase Program Board of Directors-approved share repurchase program 3M IPC 3M Innovative Properties Company 3PL Agent logistics agent 401(k) Plan 401(k) retirement and savings plan AAHI Access to Advanced Health Institute ACA Affordable Care Act ADCC antibody-dependent cellular cytotoxicity ALC absolute lymphocyte count Altor Altor BioScience, LLC America Invents Act Leahy-Smith America Invents Act Amyris Amyris, Inc.
ANC absolute neutrophil count aNK activated NK cells ANKTIVA Proprietary name for N-803 (formerly ALT-803), our novel IL-15 receptor superagonist complex (nogapendekin alfa inbakicept-pmln) currently approved for use in the United States with BCG for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors, and currently in clinical development for other indications.
Annual Report Annual Report on Form 10-K for the year ended December 31, 2024 Approved product ANKTIVA ART anti-retroviral therapy ASC Accounting Standards Codification ASCO American Society of Clinical Oncology ASU Accounting Standards Update Athenex Athenex, Inc.
BLA Biologics License Application bNAbs broadly-neutralizing antibodies BPCIA Biologics Price Competition and Innovation Act of 2009 Brink Brink Biologics, Inc.
Cambridge Cambridge Equities, LP CAR chimeric antigen receptor CCPA California Consumer Privacy Act of 2018 CEO chief executive officer i Term Definition CFO chief financial officer cGMP current Good Manufacturing Practice China when used in connection with the RIPA, People s Republic of China, Hong Kong and any territories controlled by the People s Republic of China CI confidence interval CIO chief information officer CIS carcinoma in situ Clinic Immuno-Oncology Clinic, Inc.
Closing Date when used in connection with the RIPA, December 29, 2023 CMC Chemistry, Manufacturing and Controls CMO contract manufacturing organization CMS Centers for Medicare Medicaid Services Code Internal Revenue Code of 1986, as amended CODM chief operating decision maker CPI checkpoint inhibitor CPRA California Privacy Rights Act CR complete response CRADA Cooperative Research and Development Agreement CRL complete response letter CRO contract research organization CVR contingent value right DAMPs damage-associated molecular patterns DGCL Delaware General Corporation Law DOD U.S.
Nant Capital Nant Capital, LLC NantCell NantCell, Inc., a subsidiary of the company NANTibody Immunotherapy NANTibody, LLC, a subsidiary of the company NantKwest NantKwest, Inc.
NantMobile NantMobile, LLC NantPharma NantPharma, LLC NantWorks NantWorks, LLC, a related party NC 2015 Plan NantCell, Inc.
2015 Stock Incentive Plan NCI National Cancer Institute NCV Nant Cancer Vaccine NEO named executive officer NHL non-Hodgkin lymphoma NIAID National Institute of Allergy and Infectious Diseases NIH National Institutes of Health NIH Guidelines NIH Guidelines for Research Involving Recombinant DNA Molecules NK natural killer NMIBC non-muscle invasive bladder cancer NOL net operating loss NSCLC non-small cell lung cancer OBA NIH Office of Biotechnology Activities Oberland Oberland Capital Management LLC and its affiliates (including Purchasers as defined in the RIPA) OFAC U.S.
Treasury Department s Office of Foreign Assets Control PCAOB Public Company Accounting Oversight Board (United States) PD-1 programmed death receptor 1 PD-L1 programmed death receptor ligand PDMA U.S.